Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage (NCT07305896) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage
1,248 participantsStarted 2025-12-31
Plain-language summary
This study plans to enroll 1248 patients with supratentorial ICH within 24 hours of onset across multiple stroke centers. After randomization, the control group will only receive medical therapy. The experimental group, after randomization, will receive an initial dose of 200 mg of minocycline hydrochloride capsules in addition to medical ttherapy, followed by 100 mg orally every 12 hours for 7 days, resulting in a total of 14 administrations. Both groups will be followed for 180 days to evaluate the efficacy and safety of minocycline in the treatment of ICH.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥ 18 years, regardless of gender;
. Supratentorial ICH confirmed by brain CT scan;
. No disability in the community before ICH (premorbid mRS≤1);
. Neurological deficits related to the hematoma, with NIHSS score ≥ 6 and single-limb motor item score ≥ 2;
. GCS score ≥ 6;
. Able to initiate the first dose of minocycline within 24 hours of onset;
. Signed and dated informed consent.
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The proportion of patients with favorable functional outcomes, defined as mRS 0-2 at 180 days.
. Definite evidence of secondary ICH, such as structural abnormality, brain aneurysm, brain tumor, use of thrombolytic drugs;
. Allergy to tetracycline antibiotics;
. Use of vitamin A derivatives or steroid therapy within the past 3 months;
. Concomitant infection requiring antibiotic treatment at admission;
. Planned surgical intervention;
. Life expectancy of less than 6 months due to comorbid conditions;
. Severe hepatic and renal dysfunction, or AST and/or ALT \>3 times the upper limit of reference range, or serum creatinine \>265 μmol/L (\> 3 mg/dL);
. Bleeding tendency, including heparin use within the past 48 hours (APTT ≥ 35 s), oral warfarin (INR \> 2), platelet count \< 100 × 10⁹/L, or hereditary hemorrhagic diseases;